偏头痛与三叉神经血管系统:40年回顾
本文回顾了1979年《柳叶刀》提出的三叉神经血管假说及其对偏头痛理解的转变。该假说推动了神经肽在偏头痛机制中的作用、抗偏头痛药物阻断神经肽释放以及三叉神经传入激活和敏化等关键概念的发展,并最终促成了针对CGRP及其受体的治疗策略。
要点
- 三叉神经血管系统在偏头痛中具有基础性作用。
- 神经肽研究为抗CGRP及其受体的单克隆抗体疗法奠定基础。
- 该假说为未来偏头痛治疗提供了路线图。
核心结论
- 三叉神经血管系统被广泛认为在偏头痛这一高度复杂的神经疾病中具有基础性作用。
研究设计与样本
- 本文为综述,回顾1979年《柳叶刀》提出的三叉神经血管假说及相关研究进展。
主要发现
- 1979年提出的假说认为含神经肽的三叉神经具有整合作用,推动了偏头痛领域的转变。
- 研究揭示了神经肽及其从脑膜三叉神经末梢释放参与偏头痛机制。
- 抗偏头痛药物可阻断神经肽释放,脑膜炎症刺激可激活和敏化三叉神经传入。
- 针对CGRP和P物质的反血清可中和其作用,为神经肽研究提供了首个证据。
临床怎么用
- 针对CGRP及其受体的单克隆抗体是基于该假说发展的成功治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The underlying causes of migraine headache remained enigmatic for most of the 20th century. In 1979, The Lancet published a novel hypothesis proposing an integral role for the neuropeptide-containing trigeminal nerve. This hypothesis led to a transformation in the migraine field and understanding of key concepts surrounding migraine, including the role of neuropeptides and their release from meningeal trigeminal nerve endings in the mechanism of migraine, blockade of neuropeptide release by anti-migraine drugs, and activation and sensitisation of trigeminal afferents by meningeal inflammatory stimuli and upstream role of intense brain activity. The study of neuropeptides provided the first evidence that antisera directed against calcitonin gene-related peptide (CGRP) and substance P could neutralise their actions. Successful therapeutic strategies using humanised monoclonal antibodies directed against CGRP and its receptor followed from these findings. Nowadays, 40 years after the initial proposal, the trigeminovascular system is widely accepted as having a fundamental role in this highly complex neurological disorder and provides a road map for future migraine therapies.
引用
- Ashina M, Hansen JM, Do TP, et al. Migraine and the trigeminovascular system-40 years and counting. Lancet Neurol. 2019. PMID: 31160203. doi:10.1016/S1474-4422(19)30185-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。